Methotrexate: First-line or second-line immunomodulator?

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 3, 2003, Pages 225-231

  Fraser, Alan G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Crohn's disease; Methotrexate; Rheumatoid arthritis; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; FOLIC ACID; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ANTIINFLAMMATORY ACTIVITY; CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; CYTOTOXICITY; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; HUMAN; LIVER DISEASE; LUNG TOXICITY; NAUSEA; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMATITIS; TOXICITY TESTING; VOMITING;

ARTHRITIS, RHEUMATOID; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; METHOTREXATE;

EID: 0037340410     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200303000-00003     Document Type: Review

References (68)

1. Rutgeerts PJ. Limitations of corticosteroid therapy in Crohn's disease. Aliment Pharmacol Ther 2001; 15:1515-1525.
2. Fraser AG, Orchard T, Jewell DP. The safety and efficacy of azathioprine for the treatment of inflammatory bowel disease - a 30-year audit. Gut 2002; 50:485-489. A review of 622 patients with Crohn's disease and ulcerative colitis treated with azathioprine. The 3 year remission rate was 69%. The duration of azathioprine treatment did not affect the relapse rate after stopping treatment.
3. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn's disease treated with azathioprine and 6-mercaptopurine. Lancet 1996; 347:215-219.
4. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997; 23:739-755. Report on an excellent symposium on methotrexate treatment for rheumatoid arthritis. Many issues are relevant to gastroenterologists.
5. Barrera P, Haagsma CJ, Boerbooms AM, van Riel PL, Borm GF, van der Putte LB, et al. Effect of methotrexate alone or in combination with sulphasalazine on the production of circulating concentrations of cytokines and their antagonists: longitiudinal evaluations in patients with rheumatoid arthritis. Br J Rheum 1995; 34:747-755.
6. Bannwarth B, Phourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30:194-210. Useful review of the pharmacokinetics of methotrexate.
7. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40:723-757.
8. Moshkowitz M, Oren R, Tishler M, Konikoff FM, Graft E, Brill S, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11:569-573.
9. Hillson JL, Furst DE. Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Rheum Dis Clin North Am 1997; 23:757-778.
10. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35:409-412.
11. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, et al. A randomised dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1597-1604.
12. Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low-dose methotrexate. A regional survey. J Rheumatol 1993; 20:1121-1125.
13. Ward MM. Trends in the use of disease modifying anti-rheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Care Surveys. J Rheumatol 1999; 26:546-550.
14. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818-822. Pivotal study showing short-term efficacy of methotrexate for treatment of rheumatoid arthritis.
15. Williams HJ, Willkens RF, Samuelson CO Jr, Alarc GS, Guttadauria M, Yarboro C, et al. Comparison of low-dose pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28:721-730.
16. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 1997; 40:984-985. Excellent long-term tolerability in 29 patients with rheumatoid arthritis studied from 1982 - 51% continued treatment long-term.
17. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long-term prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998; 25:238-242. Another study showing good long-term tolerability in 26 patients; three discontinued treatment (two had pneumonitis).
18. Willkens RF, Sharp JT, Stablein D, Marks C, Wortmann R. Comparison of azathioprine, methotrexate and the combination of the two in the treatment of rheumatoid arthritis: a forty-eight week controlled clinical trial with radiological outcome assessment. Arthritis Rheum 1995; 38:1799-1806.
19. Hamdy H, McKendry RJ, Mierins E, Liver JA. Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arthritis Rheum 1987; 30:361-368.
20. Jeurissen ME, Boerbooms AM, van der Putte LB. Superiority of methotrexate to azathioprine in advanced rheumatoid arthritis: results of randomised double-blind trial. Arthritis Rheum 1990; 33 (suppl 9):S39.
21. Arnold MH, O'Callaghan J, McCredie M, Beller EM, Kelly DE, Brooks PM. Comparative controlled trial of low-dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3-year prospective study. Br J Rheumatol 1990; 29:120-125.
22. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of all three medications. Arthritis Rheum 2002; 46:1164-1170.
23. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-1939. Combination of methotrexate and infliximab better than methotrexate alone for rheumatoid arthritis.
24. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Int Med 1989; 110:353-356. First report on methotrexate for inflammatory bowel disease.
25. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, et al., for the North American Crohn's Study Group Investigators. Methotrexate in the treatment of Crohn's disease. N Engl J Med 1995; 332:292-297. Landmark placebo controlled trial that confirmed the efficacy of weekly intramuscular methotrexate (25 mg) for the treatment of Crohn's disease. Remission rate of 39% in the methotrexate group compared with 19% in the placebo group (P = 0.025).
26. Fraser AG, Morton D, McGovern DPB, Travis SPL, Jewell DP. The efficacy of methotrexate treatment for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:693-697. A retrospective review of long-term remission rates with methotrexate. Useful data on relapse rates after stopping treatment.
27. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15:35-44. A retrospective review confirming good long-term remission rates. Data suggest better efficacy for parenteral treatment.
28. Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud J-C, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterology 2000; 95:1730-1734. Another good retrospective review showing excellent remission rates and tolerability.
29. Baron TH, Truss CD, Elson CO. Low-dose methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38:1851-1856.
30. Cheetman BC, Harris MS. Efficacy and safety of subcutaneous methotrexate in Crohn's disease. Gastroenterology 1995; 108:A796.
31. Mahadevan U, Marion JF, Present DH. The place of methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 1997; 112:1031.
32. Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflam Bowel Dis 1999; 5:11-15.
33. Alvarez F, Dallavis J, O'Brien J. The role of methotrexate therapy in the management of patients with cyclosporin A-resistant inflammatory bowel disease. Gastroenterology 1996; 110:A853.
34. Aurora S, Katlov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomised, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46:1724-1729.
35. Hamilton RA, Kremer JM. Why intramuscular dosing may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36:86-90.
36. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, et al. Methotrexate in chronic active Crohn's disease: a double-blind randomised, Israel multicentre trial. Am J Gastroenterol 1997; 92:2203-2209. Useful placebo controlled trial with negative results - may have been due to the low dose used, 12.5 mg orally, but this defines the lower dose limit.
37. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342:1664-1666. A large placebo controlled trial of maintenance treatment over 40 weeks. The remission rate on methotrexate 15 mg i.m. weekly was 65% compared with 39% on placebo (P = 0.04).
38. Kozarek RA, Patterson DJ, Gelfand MD, Ball TJ, Botoman VA. Long-term use of methotrexate in inflammatory bowel disease. Gastroenterology 1992; 102:A648.
39. Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomised, Israeli multicentre trial. Gastroenterology 1996; 110:1416-1421.
40. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12:1227-1233.
41. O'Donoghue DP, Dawson AM, Powell-Tuck K, Bown RT, Lennard-Jones JE, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; ii:955-957.
42. Ardizzone S, Bollani S, Manzionna BG, et al. Controlled trial comparing intravenous methotrexate and oral azathioprine for chronic active Crohn's disease: preliminary report. Gastroenterology 1999; 116:A662.
43. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JK, van Deventer SJ. Infliximab treatment for Crohn's disease. One-year experience in a Dutch academic hospital. Inflam Bowel Dis 2002; 8:81-86. The best results with infliximab treatment were achieved in patients on methotrexate.
44. Hommes D, Deley M, Sterringa G, Bartelsman J, van Deventer S. Methotrexate therapy for Crohn's disease: long-term efficacy and safety. Gastroenterology 2002; 122:A500.
45. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumour necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001; 96:1977-1997.
46. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind placebo-controlled trial. Ann Int Med 1994; 121:833-841. Important study that confirmed that folic acid can reduce gastrointestinal side-effects without reducing efficacy.
47. Van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001; 44:1515-1524. This study shows that folic acid has a similar effect to folinic acid.
48. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88:589-592.
49. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90:711.
50. Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME. Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol 1997; 36:210-213.
51. Walker AM, Funch D, Dreyer NA, Tolamn KG, Kremer JH, Alarcon GS, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993; 36:329-335.
52. Bergquist SR, Felson DT, Prashker MJ, Freeberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995; 38:326-333.
53. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995; 38:1115-1119.
54. Kremer JM, Alarc GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37:316-328. Liver biopsy only required for persistent elevation of ALT - five out of nine tests over a 12 month period.
55. West SG. Methotrexate hepatotoxicity. Rheum Clin North Am 1997; 23:883-915.
56. Te HS, Schiano TD, Kuan SF, Hanauer SB. Is long-term methotrexate use hepatotoxic in inflammatory bowel disease patients? Gastroenterology 1999; 116:A575. This small study represents the greatest reported experience of liver histology in methotrexate treatment of inflammatory bowel disease.
57. Cunliffe RN, Scott BB. Monitoring for drug side-effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16:647-662.
58. Kremer JM, Alarc GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multi-centre study with literature review. Arthritis Rheum 1997; 40:1829-1837.
59. Cannon GW. Methotrexate pulmonary toxicity. Rheum Dis Clin North Am 1997; 23:917-937.
60. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. J Rheumatol 2002; 41:262-267.
61. Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23:955-967.
62. Kremer JM. Is methotrexate oncogenic in patients with rheumatoid arthritis? Semin Arthritis Rheum 1997; 26:785-787.
63. Asten P, Barrett J, Symmon D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatoid arthritis. J Rheumatol 1999; 26:1705-1714. A large study assessing the malignancy risk from azathioprine or methotrexate. Azathioprine was found to increase the risk of lymphoma. No effect was seen with methotrexate.
64. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173-1177. Very provocative study showing that methotrexate treatment reduced overall mortality by decreasing cardiovascular deaths.
65. Modigliani R. Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 2000; 6:251-257.
66. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46:894-898.
67. Kremer J. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Int Med 2001; 134:695-706. Comprehensive review of the current position in rheumatology practice for methotrexate treatment, including combination therapy and the clinical place of the new biological treatments.
68. Wolfe F, Pincus T, Fries JF, and the Inception Cohort Group. Use of second-line "disease modifying" anti-rheumatic drugs within 5 months of disease onset by 64% of 750 rheumatoid arthritis patients under the care of 142 US rheumatologists: an inception cohort study. Arthritis Rheum 1997; 40:S218.